Skip to main content

Sernova Biotherapeutics Inc(SVA-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.1750
Day High0.1800
Open:0.1750
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
INK Research
Off-market insider buying at Sernova Biotherapeutics (SVA)
Company Chart of SVA
Newsfile
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
Baystreet
Stocks in play: Sernova Biotherapeutics
Newsfile
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
Motley Fool
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
Motley Fool
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share
Baystreet
Stocks in play: Sernova Biotherapeutics
Newsfile
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
Newsfile
Sernova Biotherapeutics Announces Warrant Amendments
Motley Fool
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
Newsfile
Upcoming Meeting Dates - February 2, 2026
GlobeNewswire
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
Newsfile
Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts
Newswire.ca
Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
Baystreet
Stocks in play: Sernova Biotherapeutics
Newsfile
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
GlobeNewswire
Sernova Appoints Jonathan Rigby as Interim Chair
GlobeNewswire
Chair of Sernova Biotherapeutics Resigns
Baystreet
Stocks in play: Sernova Biotherapeutics
GlobeNewswire
Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes
GlobeNewswire
Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans
GlobeNewswire
Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med
Newswire.ca
Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share
GlobeNewswire
Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes
Newswire.ca
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
Stock Target Advisor
Sernova Corp Stock Forecast: What to Expect from Q1 2025 Earnings
Sernova Corp Stock Forecast: What to Expect from Q1 2025 Earnings
GlobeNewswire
Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D
GlobeNewswire
Sernova Biotherapeutics Secures $1 Million Convertible Debt Financing
GlobeNewswire
Sernova Biotherapeutics Receives FDA Clearance for IND Application for its Cell Pouch Bio-hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism
GlobeNewswire
Sernova Biotherapeutics Submits IND Application for its Cell Pouch Bio-Hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism
Baystreet
Jobs Reports Due for Next Week
Stock Target Advisor
Sernova Corp (SVA:CA) Stock Forecast: Analyst Ratings and Key Updates
Sernova Corp (SVA:CA) Stock Forecast: Analyst Ratings and Key Updates

Profile

Sernova Biotherapeutics Inc is a clinical-stage biotechnology company focused on advancing regenerative medicine for the treatment of chronic diseases. The Company's primary asset is its proprietary Cell Pouch, a bio-hybrid organ system designed to enhance the delivery of cell therapy by replicating natural body functions. The Cell Pouch creates a vascularized, organ-like environment that promotes the longevity and functionality of therapeutic cells and ensures containment for retrievability.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.